Marina Biotech makes organisational changes
Creates the position of executive vice president of r&d
Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.
In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.
Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.
Finally, Alan Dunton has joined the firm as consulting chief medical officer.
Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.
You may also like
Research & Development
Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells
Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies